X-Linked Adrenoleukodystrophy: Overview and Prognosis as a Function of Age and Brain Magnetic Resonance Imaging Abnormality. A Study Involving 372 Patients

H. W. Moser; D. J. Loes; E. R. Melhem; G. V. Raymond; Lena Bezman; Christiane S. Cox; Shou-en Lu

doi:10.1055/s-2000-9236

Neuropediatrics, Inhaltsverzeichnis

Neuropediatrics 2000; 31(5): 227-239
DOI: 10.1055/s-2000-9236

The Peter Emil Becker Memorial Lecture 1999

Georg Thieme Verlag Stuttgart · New York

X-Linked Adrenoleukodystrophy: Overview and Prognosis as a Function of Age and Brain Magnetic Resonance Imaging Abnormality. A Study Involving 372 Patients

H. W. Moser¹ , D. J. Loes² , E. R. Melhem³ , G. V. Raymond¹ , Lena Bezman¹ , Christiane S. Cox¹ , Shou-en Lu⁴

¹ Kennedy Krieger Institute and Department of Neurology, Johns Hopkins Medical Institutions, Baltimore, USA
² Suburban Radiologic Consultants Ltd., Minneapolis, USA
³ Department of Radiology and Radiological Sciences, The Johns Hopkins Medical Institutions, Baltimore, USA
⁴ Departments of Biostatistics, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, USA

Abstract

The phenotypic expression of X-linked adrenoleukodystrophy (X-ALD) ranges from the rapidly progressive childhood cerebral form to the milder adrenomyeloneuropathy (AMN) in adults. It is not possible to predict phenotype by mutation analysis or biochemical assays. This study reports on 372 patients ranging in age from less than 3 years to adulthood, who have been followed at the Kennedy Krieger Institute. With the aim of determining whether a method could be developed to predict clinical course by analysis of data available at time of first contact, the patients were subdivided into 18 subgroups on the basis of age and the extent of brain magnetic resonance (MRI) abnormality utilizing the MRI scoring system devised by Loes et al. Scores to grade degree of neurologic and neuropsychologic impairment were also developed. There was strong correlation between MRI and the neurology and neuropsychology scores at baseline. Information based exclusively on age and MRI score at time of first contact was highly predictive of future clinical course and should aid the evaluation of the effects of bone marrow transplantation and the selection of patients for this procedure, as well as the evaluation of other therapies that may be developed in the future.

Key words

Adrenoleukodystrophy - Therapy - Bone marrow transplant - Magnetic resonance imaging - Magnetic resonance spectroscopy - Prognosis - Phenotypes - Natural history

Volltext

Referenzen

References

1 Aubourg P. X-Linked Adrenoleukodystrophy. Handbook of Clinical Neurology. Amsterdam; Elsevier 1996
2 Aubourg P, Adamsbaum C, Lavallard-Rousseau M C, Rocchiccioli F, Cartier N, Jambaque I. et al . A two-year trial of oleic and erucic acids (“Lorenzo's oil”) as treatment for adrenomyeloneuropathy. N Engl J Med. 1993; 329 745-752
3 Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C. et al . Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med. 1990; 322 1860-1866
4 Benton A L, Hamsher K, Varney N, Spreen O. Judgement of Line Orientation. Contributions to Neuropsychological Assessment. New York; Oxford University Press 1983
5 Benton A L, Hamsher K, Varney N, Spreen O. Contributions to Neuropsychological Assessment. New York; Oxford University Press 1983
6 Bezman L, Moser H W. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet. 1998; 76 415-419
7 Boehm C D, Cutting G R, Lachtermacher M B, Moser H W, Chong S S. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab. 1999; 66 128-136
8 Boles D J, Craft D A, Padgett D A, Loria R M, Rizzo W B. Clinical variation in X-linked adrenoleukodystrophy: fatty acid and lipid metabolism in cultured fibroblasts. Biochem Med Metab Biol. 1991; 45 74-91
9 Braiterman L T, Watkins P A, Moser A B, Smith K D. Peroxisomal very long chain fatty acid beta-oxidation activity is determined by the level of adrenoleukodystrophy protein (ALDP) expression. Mol Genet Metab. 1999; 66 91-99
10 Braiterman L T, Zheng S, Watkins P A, Geraghty M T, Johnson G, McGuinness M C. et al . Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins. Hum Mol Genet. 1998; 7 239-247
11 Bushke H. Selective reminding for analysis of memory and learning. Journal of Verbal Learning and Behavior. 1973; 12 543-550
12 Cartier N, Lopez J, Moullier P, Rocchiccioli F, Rolland M O, Jorge P. et al . Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc Natl Acad Sci USA. 1995; 92 1674-1678
13 Confort-Gouny S, Vion-Dury J, Chabrol B, Nicoli F, Cozzone P J. Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy. Neuroradiology. 1995; 37 568-575
14 Costakos D, Abramson R K, Edwards J G, Rizzo W B, Best R G. Attitudes toward presymptomatic testing and prenatal diagnosis for adrenoleukodystrophy among affected families. Am J Med Genet. 1991; 1 295-300
15 Delis D C, Kramer J H, Kaplan E, Ober B A. California Verbal Learning Test: Child Version. San Antonio, TX; The Psychological Corporation 1987
16 Dodd A, Rowland S A, Hawkes S L, Kennedy M A, Love D R. Mutations in the adrenoleukodystrophy gene. Hum Mutat. 1997; 9 500-511
17 Dubois-Dalcq M, Feigenbaum V, Aubourg P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci. 1999; 22 4-12
18 Dunn L M, Dunn L M. Peabody Picture Vocabulary Test - Revised. Circle Pines, MN; American Guidance Service 1981
19 Forss-Petter S, Werner H, Berger J, Lassmann H, Molzer B, Schwab M H. et al . Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J Neurosci Res. 1997; 50 829-843
20 Gartner J, Braun A, Holzinger A, Roerig P, Lenard H G, Roscher A A. Clinical and genetic aspects of X-linked adrenoleukodystrophy. Neuropediatrics. 1998; 29 3-13
21 Higgins C F. ABC transporters: From microorganisms to man. Annu Rev Cell Biol. 1992; 8 67-113
22 Igarashi M, Schaumburg H H, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem. 1976; 26 851-860
23 Kaplan P W, Tusa R J, Shankroff J, Heller J, Moser H W. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann Neurol. 1993; 34 169-174
24 Kaufman A S, Kaufman N L. KABC Kaufman Assessment Battery for Children. Circle Pines, MN; American Guidance Service 1983
25 Kemp S, Wei H M, Lu J F, Braiterman L T, McGuinness M C, Moser A B. et al . Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med. 1998; 4 1261-1268
26 Kobayashi T, Shinnoh N, Kondo A, Yamada T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem Biophys Res Commun. 1997; 232 631-636
27 Kok F, Neumann S, Sarde C O, Zheng S, Wu K H, Wei H M. et al . Mutational analysis of patients with X-linked adrenoleukodystrophy. Hum Mutat. 1995; 6 104-115
28 Korenke G C, Christen H J, Kruse B, Hunneman D H, Hanefeld F. Progression of X-linked adrenoleukodystrophy under interferon-beta therapy. J Inherit Metab Dis. 1997; 20 59-66
29 Korenke G C, Pouwels P JW, Frahm J, Hunneman D H, Stoeckler S, Krasemann E. et al . Arrested cerebral adrenoleukodystrophy: A clinical and proton MRS study in 3 patients. Pediatr Neurol. 1996; 15 103-107
30 Krasemann E W, Meier V, Korenke G C, Hunneman D H, Hanefeld F. Identification of mutations in the ALD-gene of 20 families with adrenoleukodystrophy/adrenomyeloneuropathy. Hum Genet. 1996; 97 194-197
31 Krivit W, Lockman L A, Watkins P A, Hirsch J, Shapiro E G. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis. 1995; 18 398-412
32 Krivit W, Peters C, Shapiro E G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, manosidosis, fucosidosis, aspartylglutaminuria, Hurler Maroteaux-Lamy and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 1999; 12 167-176
33 Krivit W, Shapiro E, Lockman L, Torres F, Stillman A E, Moser A. et al . Recommendations for treatment of childhood cerebral form of adrenoleukodystrophy. Hobbs JR, Riches PG Correction of Certain Genetic Diseases by Transplantation. London; COGENT Trust 1992: 38-49
34 Kruse B, Barker P B, van Zijl P C, Duyn J H, Moonen C T, Moser H W. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol. 1994; 36 595-608
35 Kumar A J, Rosenbaum A E, Naidu S, Wener L, Citrin C M, Lindenberg R. et al . Adrenoleukodystrophy: correlating MR imaging with CT. Radiology. 1987; 165 497-504
36 Ladenson P W. Adrenoleukodystrophy. JAMA. 1989; 262 1504-1506
37 Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci USA. 1988; 85 7647-7651
38 Ligtenberg M J, Kemp S, Sarde C O, van Geel B M, Kleijer W J, Barth P G. et al . Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein. Am J Hum Genet. 1995; 56 44-50
39 Loes D J, Hite S, Moser H, Stillman A E, Shapiro E, Lockman L. et al . Adrenoleukodystrophy: a scoring method for brain MR observations. Am J Neuroradiol. 1994; 15 1761-1766
40 Lombard-Platet G, Savary S, Sarde C O, Mandel J L, Chimini G. A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Proc Natl Acad Sci USA. 1996; 93 1265-1269
41 Lu J F, Lawler A M, Watkins P A, Powers J M, Moser A B, Moser H W. et al . A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci USA. 1997; 94 9366-9371
42 Maestri N E, Beaty T H. Predictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy. Am J Med Genet. 1992; 44 576-582
43 Maier E M, Roscher A A, Kammerer S, Mehnert K, Conzelmann E, Holzinger A. Prenatal diagnosis of X-linked adrenoleukodystrophy combining biochemical, immunocytochemical and DNA analyses. Prenat Diagn. 1999; 19 364-368
44 Malm G, Ringden O, Anvret M, von Dobeln U, Hagenfeldt L, Isberg B. et al . Treatment of adrenoleukodystrophy with bone marrow transplantation. Acta Paediatr. 1997; 86 484-492
45 McCarthy D. McCarthy Scales of Children's Abilities. San Antonio; The Psychological Corporation 1972
46 Melhem E R, Breiter S N, Ulug A M, Raymond G V, Moser H W. Improved tissue characterization in adrenoleukodystrophy using magnetization transfer imaging. Am J Roentgenol. 1996; 166 689-695
47 Melhem E R, Loes D J, Georgiades C S, Raymond G V, Moser H W. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. Am J Neuroradiol. 2000; 21 839-844
48 Migeon B R, Moser H W, Moser A B, Axelman J, Sillence D, Norum R A. Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci USA. 1981; 78 5066-5070
49 Moser A B, Kreiter N, Bezman L, Lu S, Raymond G V, Naidu S. et al . Plasma very long chain fatty acids in 3000 peroxisome disease patients and 29, 000 controls. Ann Neurol. 1999; 45 100-110
50 Moser A B, Moser H W. The prenatal diagnosis of X-linked adrenoleukodystrophy. Prenat Diagn. 1999; 19 46-48
51 Moser H W. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain. 1997; 120 1485-1508
52 Moser H W, Bergin A, Naidu S, Ladenson P W. Adrenoleukodystrophy. Endocrinol Metab Clin North Am. 1991; 20 297-318
53 Moser H W, Borel J. Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr. 1995; 15 379-397
54 Moser H W, Tutschka P J, Brown F R, Moser A E, Yeager A M, Singh I. et al . Bone marrow transplant in adrenoleukodystrophy. Neurology. 1984; 34 1410-1417
55 Mosser J, Douar A M, Sarde C O, Kioschis P, Feil R, Moser H. et al . Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature. 1993; 361 726-730
56 Mosser J, Lutz Y, Stoeckel M E, Sarde C O, Kretz C, Douar A M. et al . The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet. 1994; 3 265-271
57 Naidu S, Bresnan M J, Griffin D, O'Toole S, Moser H W. Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol. 1988; 45 846-848
58 Pai G S, Khan M, Barbosa E, Key L, Craver J R, Cure J K. et al . Lovastatin therapy for X-linked adrenoleukodystrophy: Clinical and biochemical observations on twelve patients. Mol Genet Metab. 2000; 69 312-322
59 Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Ann Neurol. 1994; 36 741-746
60 Pouwels P J, Kruse B, Korenke G C, Mao X, Hanefeld F A, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics. 1998; 29 254-264
61 Powers J M, DeCiero D P, Ito M, Moser A B, Moser H W. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol. 2000; 59 89-102
62 Powers J M, Liu Y, Moser A B, Moser H W. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol. 1992; 51 630-643
63 Rajanayagam V, Grad J, Krivit W, Loes D J, Lockman L, Shapiro E. et al . Proton MR spectroscopy of childhood adrenoleukodystrophy. Am J Neuroradiol. 1996; 17 1013-1024
64 Rasmussen M, Moser A B, Borel J, Khangoora S, Moser H W. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem Res. 1994; 19 1073-1082
65 Raven J. Raven Progressive Matrices - Research Supplement #3. San Antonio; The Psychological Corporation 1986
66 Rey A. L'examen psychologique dans les cas d'encéphalopatie traumatique. Archives De Psychologie. 1941; 28 268-345
67 Rizzo W B. Lorenzo's oil - hope and disappointment [editorial]. N Engl J Med. 1993; 329 801-802
68 Rizzo W B, Leshner R T, Odone A, Dammann A L, Craft D A, Jensen M E. et al . Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology. 1989; 39 1415-1422
69 Ruiz M, Coll M J, Pampols T, Giros M. ALDP expression in fetal cells and its application in prenatal diagnosis of X-linked adrenoleukodystrophy. Prenat Diagn. 1997; 17 651-656
70 Schaumburg H H, Powers J M, Raine C S, Suzuki K, Richardson E P. Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol. 1975; 32 577-591
71 Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M. et al . Long-term beneficial effect of bone marrow transplantation for childhood onset cerebral X-linked adrenoleukodystrophy. Lancet. 2000; 356 713-718
72 Shapiro E G, Klein K A. Dementia in childhood: Issues in neuropsychological assessment with application to the natural history and treatment of degenerative storage diseases. Tramontana MG, Hooer SR Advances in Child Neuropsychology. New York; Springer-Verlag 1994: 119-171
73 Shapiro E G, Lockman L A, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis. 1995; 18 413-429
74 Singh I, Moser A E, Goldfischer S, Moser H W. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci USA. 1984; 81 4203-4207
75 Singh I, Pahan K, Khan M. Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett. 1998; 426 342-346
76 Smith K D, Kemp S, Braiterman L T, Lu J F, Wei H M, Geraghty M. et al . X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res. 1999; 24 521-535
77 Smith K D, Sack G, Beaty T, Bergin A, Naidu S, Moser A. et al . A genetic basis for the multiple phenotypes of X-linked adrenoleukodystrophy. Am J Hum Genet. 1991; 49 864 a
78 Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York, NY; Oxford University Press 1991
79 Stanislaus R, Pahan K, Singh A K, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett. 1999; 269 71-74
80 Steinberg S J, Kemp S, Braiterman L T, Watkins P A. Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy. Ann Neurol. 1999; 46 409-412
81 Steinberg S J, Wang S J, McGuinness M C, Watkins P A. Human liver-specific very-long-chain acyl-coenzyme A synthetase: cDNA cloning and characterization of a second enzymatically active protein. Mol Genet Metab. 1999; 68 32-42
82 Takano H, Koike R, Onodera O, Sasaki R, Tsuji S. Mutational analysis and genotype-phenotype correlation of 29 unrelated Japanese patients with X-linked adrenoleukodystrophy. Arch Neurol. 1999; 56 295-300
83 Tourbah A, Stievenart J L, Iba-Zizen M T, Lubetzki C, Baumann N, Eymard B. et al . Localized proton magnetic resonance spectroscopy in patients with adult adrenoleukodystrophy. Increase of choline compounds in normal appearing white matter. Arch Neurol. 1997; 54 586-592
84 Tzika A A, Ball W S, Vigneron D B, Dunn R S, Kirks D R. Clinical proton MR spectroscopy of neurodegenerative disease in childhood. Am J Neuroradiol. 1993; 14 1267-1281
85 Uchiyama A, Aoyama T, Kamijo K, Uchida Y, Kondo N, Orii T. et al . Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase. J Biol Chem. 1996; 271 30 360-30 365
86 van Geel B M, Assies J, Haverkort E B, Koelman J H, Verbeeten B, Wanders R J. et al . Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo's oil”. J Neurol Neurosurg Psychiatry. 1999; 67 290-299
87 van Geel B M, Assies J, Wanders R J, Barth P G. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry. 1997; 63 4-14
88 Wechsler D. Wechsler Preschool and Primary Scale of Intelligence - Revised (WPPSI-R). San Antonio; The Psychological Corporation 1989
89 Wechsler D. Wechsler Intelligence Scale for Children Third Edition (WISC III). San Antonio; The Psychological Corporation 1991
90 Woodcock R W, Mather N. Woodcock Johnson Psychoeducational Battery Tests of Achievement - Revised. Allen, TX; DLM Teaching Resources 1972
91 Zinkham W H, Kickler T, Borel J, Moser H W. Lorenzo's oil and thrombocytopenia in patients with adrenoleukodystrophy [letter]. N Engl J Med. 1993; 328 1126-1127

M. D. Hugo W. Moser

Kennedy Krieger Institute

707 North Broadway

Baltimore, MD 21205

USA